A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman.

Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...

Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred Further validating its advanced transcatheter aortic valve implantation (TAVI)...

The Boston Scientific Lotus™ Valve System advanced TAVR technology continued to demonstrate impressive performance at three months, according to new data presented at ACC 2014. The REPRISE II...

Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment Marking a major step forward in the evolution of...